Acquired resistance to chemotherapy in lung cancer cells mediated by prolonged nitric oxide exposure

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5433-5444

  Wongvaranon, Piyaparisorn ^a   Pongrakhananon, Varisa ^a   Chunhacha, Preedakorn ^a   Chanvorachote, Pithi ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Chemotherapeutic resistance; Cisplatin; Doxorubicin; Etoposide; Lung cancer; Nitric oxide

Indexed keywords

ANNEXIN; CAVEOLIN 1; CISPLATIN; DOXORUBICIN; ETOPOSIDE; HOE 33342; NITRIC OXIDE; PROPIDIUM IODIDE; PROTEIN BCL 2; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; LUNG CANCER; MTT ASSAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

EID: 84891421503     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. McKenzie S and Kyprianou N: Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem 97: 18-32, 2006.
2. Brader S and Eccles SA: Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90: 2-8, 2004.
3. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F and Libra M: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006.
4. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN and Larue L: The protein kinase AKT induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 63: 2172-2178, 2003.
5. Hutchinson J, Jin J, Cardiff RD, Woodgett JR and Muller WJ: Activation of AKT (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21: 2203-2212, 2001.
6. Morishita N, Tsukahara H, Chayama K, Ishida T, Washio K, Miyamura T, Yamashita N, Oda M and Morishima T: Activation of AKT is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 59: 83-89, 2012.
7. West KA, Castillo SS and Dennis PA: Activation of the PI3K/AKT pathway and chemotherapeutic resistance. Drug Resist Updat 5: 234-248, 2002.
8. Škarda J, Hajdúch M and Kolek V: Drug resistance in lungcancer. Cancer Ther 6: 377-388, 2008.
9. Ray MR and Jablons DM: Lung cancer metastasis novel biological mechanisms and impact on clinical practice. In:Hallmarks of Metastasis. Keshamouni V, Arenberg D and Kalemkerian G (eds.). New York, Springer, pp. 29-46, 2009.
10. Eastman A: Mechanisms of resistance to cisplatin. Cancer Treat Res 57: 233-249, 1991.
11. Zeng-Rong N, Paterson J, Alpert L, Tsao MS, Viallet J and Alaoui-Jamali MA: Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 55: 4760-4764, 1995.
12. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X and Yu J: Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene.Cancer Chemother Pharmacol 58: 776-784, 2006.
13. Brognard J, Clark AS, Ni Y and Dennis PA: AKT/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997, 2001.
14. Tang JM, He QY, Guo RX and Chang XJ: Phosphorylated AKT overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-191, 2006.
15. Liu LZ, Zhou XD, Qian G, Shi X, Fang J and Jiang BH: AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67: 6325-6332, 2007.
16. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simões-Wüst AP, Yousefi S, Simon HU, Stahel R and Zangemeister-Wittke U: Cisplatin activates AKT in small cell lung cancer cells and attenuates apoptosis by survivin up-regulation. Int J Cancer 117:755-763, 2005.
17. Matsuzaki H, Tamatani M, Mitsuda Ni, Namikawa K, Kiyama H, Miyake S and Tohyama M: Activation of AKT kinase inhibits apoptosis and changes in BCL2 and BAX expression induced by nitric oxide in primary hippocampal neurons. J Neurochem 73:2037-2046, 1999.
18. Ben-Ezra JM, Kornstein MJ, Grimes MM and Krystalt G: Small cell carcinomas of the lung express the BCL2 protein. Am J Pathol 145: 1036-1040, 1994.
19. Ikegaki N, Katsumata M, Minna J and Tsujimoto Y: Expression of BCL2 in small cell lung carcinoma cells. Cancer Res 54: 6-8, 1994.
20. Luanpitpong S, Talbott SJ, Rojanasakul Y, Nimmannit U, Pongrakhananon V, Wang L and Chanvorachote P: Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1. J Biol Chem 285: 38832-38840, 2010.
21. Chunhacha P and Chanvorachote P: Roles of caveolin-1 on anoikis resistance in non-small cell lung cancer. Int J Physiol Pathophysiol Pharmacol 4: 149-155, 2012.
22. Rungtabnapa P, Nimmannit U, Halim H, Rojanasakul Y and Chanvorachote P: Hydrogen peroxide inhibits non-small cell lung cancer cell anoikis through the inhibition of caveolin-1 degradation. Am J Physiol Cell Physiol 300: C235-C245, 2011.
23. Chanvorachote P and Chunhacha P: Caveolin-1 regulates endothelial adhesion of lung cancer cells via reactive oxygen species-dependent mechanism. PLoS ONE 8(2): e57466, 2013.
24. Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, Lee SD, Choi YL, Kim MK and Chung DH: Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 42: 195-202, 2003.
25. Moncada S, Palmer RM and Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142, 1991.
26. Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 6: 3051-3064, 1992.
27. Butler AR and Williams DHL: The physiological role of nitric oxide. Chem Soc Rev 22: 233-241, 1993.
28. Beckman JS, Beckman TW, Chen J, Marshall PA and Freeman BA: Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620-1624, 1990.
29. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V and Moncada S: Nitric oxide activity in human gynecological cancer. Cancer Res 54: 1352-1354, 1994.
30. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG and Moncada S: Nitric oxide synthase activity in human breast cancer. Br J Cancer 72: 41-44, 1995.
31. Franchi A, Gallo O, Paglierani M, Sardi I, Magnelli L, Masini E and Santucci M: Inducible nitric oxide synthase expression in laryngeal neoplasia: Correlation with angiogenesis. Head Neck 24: 16-23, 2002.
32. Tsukahara Y, Morisaki T, Horita Y, Torisu M and Tanaka M: Expression of inducible nitric oxide synthase in circulating neutrophils of the systemic inflammatory response syndrome and septic patients. World J Surg 22: 771-777, 1998.
33. Kooguchi K, Kobayashi A, Kitamura Y, Ueno H, Urata Y, Onodera H and Hashimoto S: Elevated expression of inducible nitric oxide synthase and inflammatory cytokines in the alveolar macrophages after esophagectomy. Critical Care Medicine 30:71-76, 2002.
34. Coleman JW: Nitric oxide in immunity and inflammation. Int Immunopharmacol 1: 1397-1406, 2001.
35. Wiseman H and Halliwell B: Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem Journal 313: 17-29, 1996.
36. Hunt CR, Sim JE, Sullivan SJ, Featherstone T, Golden W, Von Kapp-Herr C, Hock RA, Gomez RA, Parsian AJ and Spitz DR: Genomic instability and catalase gene amplification induced by chronic exposure to oxidative stress. Cancer Res 58: 3986-3992, 1998.
37. Annane D, Sanquer S, Sébille V, Faye A, Djuranovic D, Raphaël JC, Gajdos P and Bellissant E: Compartmentalised inducible nitric-oxide synthase activity in septic shock. Lancet 355: 1143-1148, 2000.
38. Puhakka A, Kinnula V, Näpänkangas U, Säily M, Koistinen P, Pääkkö P and Soini Y: High expression of nitric oxide synthases is a favorable prognostic sign in non-small cell lung carcinoma. APMIS 111: 1137-1146, 2003.
39. Liu CY, Wang CH, Chen TC, Lin HC, Yu CT and Kuo HP: Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer 78: 534-541, 1998.
40. Arias-Díaz J, Vara E, Torres-Melero J, García C, Baki W, Ramírez-Armengol JA and Balibrea JL: Nitrite/nitrate and cytokine levels in bronchoalveolar lavage fluid of lung cancer patients. Cancer 74: 1546-1551, 1994.
41. Fujimoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M, Suga M and Ando M: Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res 88: 1190-1198, 1997.
42. Mannick JB, Asano K, Izumi K, Kieff E and Stamler JS: Nitric oxide produced by human B lymphocytes inhibit apoptosis and Epstein-Barr virus reactivation. Cell 79: 1137-1146, 1994.
43. Chung HT, Pae HO, Choi BM, Billiar TR and Kim YM: Nitric oxide as a bioregulator of apoptosis. Biochem Biophys Res Commun 282: 1075-1079, 2001.
44. Kolb JP, Roman V, Mentz F, Zhao H, Rouillard D, Dugas N, Dugas B and Sigaux F: Contribution of nitric oxide to the apoptotic process in human B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 40: 243-257, 2001.
45. Chen Q, Yano T, Matsumi H, Osuga Y, Yano N, Xu J, Wada O, Koga K, Fujiwara T, Kugu K and Taketani Y: Cross-talk between FAS/FAS ligand system and nitric oxide in the pathway subserving granulosa cell apoptosis: A possible regulatory mechanism for ovarian follicle atresia. Endocrinology 146: 808-815, 2005.
46. Chanvorachote P, Nimmannit U, Wang L, Stehlik C, Lu B, Azad N and Rojanasakul Y: Nitric oxide negatively regulates FAS CD95-induced apoptosis through inhibition of ubiquitin-proteasome-mediated degradation of FLICE inhibitory protein. J Biol Chem 280: 42044-42050, 2005.
47. Chanvorachote P, Nimmannit U, Stehlik C, Wang L, Jiang BH, Ongpipatanakul B and Rojanasakul Y: Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of BCL2 ubiquitination. Cancer Res 66: 6353-6360, 2006.
48. Cui S, Reichner JS, Mateo RB and Albina JE: Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res 54:2462-2467, 1994.
49. Farias-Eisner R, Sherman MP, Aeberhard E and Chaudhuri G: Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA 91: 9407-9411, 1994.
50. Gansauge S, Nussler AK, Beger HG and Gansauge F: Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G1 arrest and an increase of the cyclin-dependent kinase inhibitor p21 WAF1/CIP1. Cell Growth Differ 9:611-617, 1998.
51. Chlichlia K, Peter ME, Rocha M, Scaffidi C, Bucur M, Krammer PH, Schirrmacher V and Umansky V: Caspase activation is required for nitric oxide-mediated, CD95(AP0-1/FAS)-dependent and independent apoptosis in human neoplastic lymphoid cells. Blood 91: 4311-4320, 1998.
52. Klein JA and Ackerman SL: Oxidative stress, cell cycle, and neurodegeneration. J Clin Invest 111: 785-793, 2003.
53. Davis KL, Martin E, Turko IV and Murad F: Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol 41: 203-236, 2001.
54. Kolb JP: Mechanisms involved in the pro- and anti-apoptotic role of NO in human leukemia. Leukemia 14: 1685-1694, 2000.
55. Sartorius UA and Krammer PH: Upregulation of BCL2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97: 584-92, 2002.
56. Song L, Coppola D, Livingston S, Cress D and Haura EB: Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 4:267-276, 2005.
57. Makin G and Hickman JA: Apoptosis and cancer chemotherapy. Cell Tissue Res 301: 143-152, 2000.
58. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N, Itoh K and Yamamoto M: NRF2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15: 3423-3432, 2009.
59. Samuels Y and Waldman T: Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 347: 21-41, 2010.
60. Storz P: Reactive oxygen species in tumor progression. Front Biosci 10: 1881-1896, 2005.
61. Feig DI, Reid TM and Loeb LA: Reactive oxygen species in tumorigenesis. Cancer Res 54: 1890s-1894s, 1994.
62. 2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749-755, 1990.
63. Liang J and Slingerland JM: Multiple roles of the PI3K/PKB (AKT) pathway in cell cycle progression. Cell Cycle 2: 336-342, 2003.
64. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997.
65. Arnelle DR and Stamler JS: NO+, NO., and NO- donation by S-nitrosothiols: implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation. Arch Biochem Biophys 318: 279-285, 1995.
66. Pongjit K and Chanvorachote P: Caveolin-1 sensitizes cisplatin-induced lung cancer cell apoptosis via superoxide anion-dependent mechanism. Mol Cell Biochem 358: 365-73, 2011.